A New Hepatitis C Medicine: Faldaprevir | Hepatitis Central

The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Menu Search
Previous

4 Hepatitis C Dietary Myths

Back to News Homepage
Next

Naomi Judd Adopts Holistic Lifestyle and Overcomes Hepatitis C

A New Hepatitis C Medicine: Faldaprevir

The Editors at Hepatitis Central
January 28, 2014

Print this page

Learn about the trial results for faldaprevir, a once-daily hepatitis C virus (HCV) NS3/4A protease inhibitor.

Faldaprevir an Anticipated Addition to HCV Armamentarium

ISSUE: JANUARY 2014 | VOLUME: 1

by David Wild

Treatment with faldaprevir, a once-daily hepatitis C virus (HCV) NS3/4A protease inhibitor, in combination with pegylated interferon (PEG-IFN) and ribavirin (RBV) led to a sustained virologic response (SVR) at week 12 in 80% of patients with HCV genotype 1, findings from a large, randomized placebo-controlled trial of the drug revealed.

Continue reading this entire article:
http://www.idse.net/ViewArticle.aspx?d=Hepatitis&d_id=213&i=January+2014&i_id=1027&a_id=25823

No Comments - be the first!
Share
Share
Previous

4 Hepatitis C Dietary Myths

Back to News Homepage
Next

Naomi Judd Adopts Holistic Lifestyle and Overcomes Hepatitis C

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.